Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Completed · Phase 1
Conditions studied: Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
In brief
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with GM-CSF, CpG 7909, and incomplete Freund's adjuvant may make a stronger immune response and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and how well vaccine therapy works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery.
Key facts
- Study ID
- NCT00471471
- Run by
- Ahmad Tarhini
- People needed
- 22
- Starts
- 2008-10-01
- Expected to finish
- 2011-12-01
- Last updated by the study team
- 2017-06-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UPMC Cancer Centers — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.